Search

Displaying results 2331 - 2340 of 10000 in total
  1. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. … It is developed by MedImmune for the treatment of Allergic Rhinitis.

    Synonyms: IMMUNOGLOBULIN G4, ANTI-(HUMAN EOTAXIN 1) (HUMAN MONOCLONAL CAT-213 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CAT-213 .KAPPA.-CHAIN, DIMER
  2. Drug

    ABT-510

    go.drugbank.com/drugs/DB05434
    Investigational

    ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth. … It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.

  3. Drug

    NAV 1800

    go.drugbank.com/drugs/DB05437
    Experimental

    RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal

  4. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

    Synonyms: IDD-1International brands: Eladem-2
  5. Drug

    Etiprednol dicloacetate

    go.drugbank.com/drugs/DB05442
    Investigational

    Etiprednol dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has been indicated in the treatment of asthma and Chron's disease.

  6. Drug

    ADL 10-0101

    go.drugbank.com/drugs/DB05443
    Experimental

    ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. … Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic doses, it is expected to avoid central nervous system side effects.

  7. Drug

    PX-12

    go.drugbank.com/drugs/DB05448
    Investigational

    PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a small-molecule inhibitor of Trx-1 (thioredoxin-1), stimulates apoptosis, down-regulates HIF-1α and vascular endothelial growth factor (VEGF) and inhibits … Since high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced

    Synonyms: 1-Methylpropyl-2-imidazolyl disulfideCategories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Smilagenin

    go.drugbank.com/drugs/DB05450
    Investigational

    Smilagenin is a novel non-peptide, orally bioavailable neurotrophic factor inducer that readily reverses free radical neurotoxicity produced by 1-ethyl-4- phenylpyridium (MPP+) in dopaminergic neurones … P58 is one of a family of phytochemicals isolated from traditional treatments for the elderly that have previously been shown to offer significant benefit in the treatment of senile dementia.

  9. Drug

    Paliroden

    go.drugbank.com/drugs/DB05454
    Investigational

    It is indicated for use in Alzheimer's Disease and Parkinson’s. … Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines.

    Synonyms: 1-(2-(Biphenyl-4-yl)ethyl)-4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine
  10. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.